Actinium Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6.95
- Today's High:
- $7.66
- Open Price:
- $7.32
- 52W Low:
- $4.67
- 52W High:
- $15.12
- Prev. Close:
- $7.36
- Volume:
- 316448
Company Statistics
- Market Cap.:
- $222.37 million
- Book Value:
- 2.223
- Revenue TTM:
- $90000
- Operating Margin TTM:
- -45026.67%
- Gross Profit TTM:
- $1.03 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -28.69%
- Return on Equity TTM:
- -61.76%
Company Profile
Actinium Pharmaceuticals Inc had its IPO on 2012-12-27 under the ticker symbol ATNM.
The company operates in the Healthcare sector and Biotechnology industry. Actinium Pharmaceuticals Inc has a staff strength of 49 employees.
Stock update
Shares of Actinium Pharmaceuticals Inc opened at $7.32 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6.95 - $7.66, and closed at $6.98.
This is a -5.16% slip from the previous day's closing price.
A total volume of 316,448 shares were traded at the close of the day’s session.
In the last one week, shares of Actinium Pharmaceuticals Inc have increased by +4.96%.
Actinium Pharmaceuticals Inc's Key Ratios
Actinium Pharmaceuticals Inc has a market cap of $222.37 million, indicating a price to book ratio of 3.8517 and a price to sales ratio of 266.6914.
In the last 12-months Actinium Pharmaceuticals Inc’s revenue was $90000 with a gross profit of $1.03 million and an EBITDA of $-40272000. The EBITDA ratio measures Actinium Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Actinium Pharmaceuticals Inc’s operating margin was -45026.67% while its return on assets stood at -28.69% with a return of equity of -61.76%.
In Q1, Actinium Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Actinium Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 6.8399
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.58 per share while it has a forward price to earnings multiple of 6.8399 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Actinium Pharmaceuticals Inc’s profitability.
Actinium Pharmaceuticals Inc stock is trading at a EV to sales ratio of 156.9242 and a EV to EBITDA ratio of -5.4741. Its price to sales ratio in the trailing 12-months stood at 266.6914.
Actinium Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $102.03 million
- Total Liabilities
- $7.86 million
- Operating Cash Flow
- $-76000.00
- Capital Expenditure
- $76000
- Dividend Payout Ratio
- 0%
Actinium Pharmaceuticals Inc ended 2024 with $102.03 million in total assets and $0 in total liabilities. Its intangible assets were valued at $102.03 million while shareholder equity stood at $57.21 million.
Actinium Pharmaceuticals Inc ended 2024 with $35.00 million in deferred long-term liabilities, $7.86 million in other current liabilities, 26000.00 in common stock, $-299802000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $94.52 million and cash and short-term investments were $94.52 million. The company’s total short-term debt was $506,000 while long-term debt stood at $0.
Actinium Pharmaceuticals Inc’s total current assets stands at $98.55 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2024, Actinium Pharmaceuticals Inc's operating cash flow was $-76000.00 while its capital expenditure stood at $76000.
Comparatively, Actinium Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $6.98
- 52-Week High
- $15.12
- 52-Week Low
- $4.67
- Analyst Target Price
- $31.8
Actinium Pharmaceuticals Inc stock is currently trading at $6.98 per share. It touched a 52-week high of $15.12 and a 52-week low of $15.12. Analysts tracking the stock have a 12-month average target price of $31.8.
Its 50-day moving average was $6.75 and 200-day moving average was $8.98 The short ratio stood at 7.38 indicating a short percent outstanding of 0%.
Around 225.8% of the company’s stock are held by insiders while 2221.6% are held by institutions.
Frequently Asked Questions About Actinium Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.